PRP Ovarian Rejuvenation: What the Evidence Actually Shows

What the procedure involves

PRP is made from your own blood. A sample is drawn and spun in a centrifuge, and the platelet-rich layer is collected. Platelets carry growth factors involved in tissue repair, which is why PRP has been tried in orthopedics, dentistry, wound care, and cosmetic treatments.

In the ovarian version, the concentrate is injected into one or both ovaries with a needle guided by transvaginal ultrasound, the same route used for egg retrieval. Clinics market it to women with diminished ovarian reserve, poor response to IVF stimulation, premature ovarian insufficiency (POI), or perimenopause. Preparation methods, volumes, and the number of injections are not standardized. Two clinics both offering "ovarian PRP" may be doing quite different things.

Why the idea caught on

The pitch is easy to understand. If growth factors help tendons and skin heal, maybe they can "wake up" dormant follicles. People with low AMH or failed IVF cycles are often told their remaining options are donor eggs or stopping. A procedure using their own blood that promises to improve their own eggs is hard to resist.

Early reports helped. Case series described women whose hormone levels improved, whose periods returned, or who conceived after PRP. Those stories are real for the people involved, but case series can't tell you what would have happened without the procedure. That gap is what randomized trials are for.

What controlled studies found

The strongest study we could find is a double-blind, placebo-controlled randomized trial by Barrenetxea and colleagues, published in Human Reproduction in 2024. It enrolled 60 women aged 30 to 42 with poor ovarian reserve (POSEIDON groups 3 and 4). Each woman had three stimulations and egg retrievals. At the first retrieval, the ovaries were injected with either PRP or saline. Neither patients nor investigators knew which.

Barrenetxea G, et al. Hum Reprod 2024;39(4):760-769. Small trial; the pregnancy comparison should not be read as proof that PRP causes harm.

Read that table carefully. PRP did yield a modestly higher total of mature eggs. Those extra eggs didn't become extra good embryos, and the chance of having at least one chromosomally normal embryo was no better. The trial was small, so the lower pregnancy rate in the PRP group shouldn't be read as evidence that PRP is harmful. It does make it very hard to argue that PRP helps.

The authors also noticed something interesting: egg numbers rose over successive retrievals in both groups. That raises the possibility that any effect comes from the needle puncture itself rather than from platelets. Their conclusion was blunt. Neither better embryo quality nor higher pregnancy rates were shown, and the findings don't support calling this "ovarian rejuvenation."

Why before-and-after results mislead

A 2025 study in the Journal of Assisted Reproduction and Genetics (Rubin and colleagues) shows clearly how this field can fool people, including well-meaning clinicians. Thirty-two low-prognosis IVF patients had in-office PRP before a repeat IVF cycle, and they were compared with 309 similar patients who simply did another cycle with no intervention.

Looked at on its own, the PRP group improved. Blastocyst, euploid, and transferable embryo yields all went up after PRP. Compared with the controls, though, no IVF outcome was significantly better. The control group improved too. The authors pointed to regression to the mean as a likely reason.

This is why a clinic's own "our patients' AMH went up after PRP" data, or a hopeful forum thread, can't answer the question you actually care about. AMH also fluctuates and is a measure of egg quantity, not a guarantee of live birth.

What professional bodies say

• ESHRE guideline on premature ovarian insufficiency (2024): its strong recommendation is that women with POI be informed "there are no interventions that have been reliably shown to increase ovarian activity and natural conception rates." The same guideline recommends that women be told oocyte (egg) donation is an established option for pregnancy after a POI diagnosis.
• ESHRE good practice recommendations on add-ons (2023): this document reviews many IVF add-ons. The section we were able to read classifies in vitro activation of dormant follicles, a different "wake up the follicles" technique, as experimental and not recommended outside strict research protocols. We could not access the paper's full clinical-management section, so we are not quoting a PRP-specific line from it here.

We did not find any major professional society that recommends ovarian PRP as routine care. If a clinic tells you otherwise, ask for the specific guideline and read it yourself.

Risks, costs, and the cost of time

The physical risks are broadly those of any transvaginal ovarian needle procedure: pain, bleeding, infection, and the risks of any sedation used. They're generally uncommon, but they aren't zero, and in many clinics PRP is billed separately from IVF.

For many people the larger risk is time. If you have diminished reserve, months spent waiting to see whether PRP "worked" are months in which reserve can keep declining. A sensible rule: PRP should never replace or delay a treatment with proven benefit unless you've made that trade-off knowingly.

If a clinic offers it: questions to ask

• Is this offered as part of a registered clinical trial? If so, what's the trial registration number, and is there a control group?
• What outcome do you track for your PRP patients: AMH, follicle count, or live births? Can I see live-birth data compared with similar patients who didn't have PRP?
• Exactly how is the PRP prepared, how much is injected, and how many sessions do you recommend?
• What will it cost all-in, including the procedure, sedation, and any extra monitoring?
• How long will it delay my next IVF cycle or other treatment?
• What would you recommend if PRP weren't an option?

A clinic that answers these openly, and frames PRP as research rather than a fix, is being honest with you. A clinic that promises "rejuvenation" isn't.

Evidence-based paths for low reserve

Low ovarian reserve narrows the options, but it doesn't close them. Depending on your age, diagnosis, and goals, the conversation with your doctor might include:

• Moving to IVF sooner rather than later, and planning for more than one retrieval to bank eggs or embryos.
• Protocol changes for poor responders. Some, like DuoStim (two retrievals in one cycle), mainly save time rather than improve odds. Others, like adjunct growth hormone, have mixed evidence.
• Donor eggs, which ESHRE describes as an established option after POI, an option many people with severely diminished reserve also consider.

Cost often shapes these choices. If price is what's keeping you from IVF, some people look at treatment abroad. colombianivf.com is a resource for people considering IVF in Colombia. Wherever you go, ask each clinic which add-ons it offers and what evidence it relies on. A clinic that is candid about experimental add-ons is a good sign.

Frequently asked questions

Sources